drugset / Trial / NCT00590954
Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas
Phase 2
Completed
32 enrolled
Memorial Sloan Kettering Cancer Center
Columbia University · collabKeryx / AOI Pharmaceuticals, Inc. · collabKeryx Biopharmaceuticals · collabOnline Collaborative Oncology Group · collabUniversity of Wisconsin, Madison · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the effectiveness of perifosine in preventing further tumor growth using the established optimal dose of the drug. A second goal is to determine if perifosine can block the molecules in the tumor that drive it to divide and grow.
Timeline
- Start
- 2006-05
- Primary completion
- 2019-11-11
- Completion
- 2019-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Perifosine | Small molecule | 100 mg | — |